These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3338271)

  • 1. Structure of C3f, a small peptide specifically released during inactivation of the third component of complement.
    Harrison RA; Farries TC; Northrop FD; Lachmann PJ; Davis AE
    Complement; 1988; 5(1):27-32. PubMed ID: 3338271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
    Ganu VS; Müller-Eberhard HJ; Hugli TE
    Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.
    Klickstein LB; Bartow TJ; Miletic V; Rabson LD; Smith JA; Fearon DT
    J Exp Med; 1988 Nov; 168(5):1699-717. PubMed ID: 2972794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3.
    Poznansky MC; Clissold PM; Lachmann PJ
    J Immunol; 1989 Aug; 143(4):1254-8. PubMed ID: 2473125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization of factor I mediated cleavage of the third component of complement.
    Davis AE; Harrison RA
    Biochemistry; 1982 Nov; 21(23):5745-9. PubMed ID: 6217832
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the structure of complement C3 and the stability of C3 derived phagocytic ligands C3b/iC3b in SJL/J and BALB/c mice.
    Lynch DM; Kay PH; Papadimitriou JM; Grounds MD
    Eur J Immunogenet; 1993 Feb; 20(1):1-9. PubMed ID: 8443150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Component C3 of hagfish complement has a unique structure: identification of native C3 and its degradation products.
    Fujii T; Nakamura T; Tomonaga S
    Mol Immunol; 1995 Jun; 32(9):633-42. PubMed ID: 7643855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
    Baatrup G; Svehag SE; Jensenius JC
    Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and characterization of bovine complement component C3 and its cleavage products.
    Di Carlo AL; Paape MJ; Hellman J; Lilius EM
    Am J Vet Res; 1997 Jun; 58(6):585-9. PubMed ID: 9185962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).
    Ueki T; Mizuno M; Uesu T; Kiso T; Nasu J; Inaba T; Kihara Y; Matsuoka Y; Okada H; Fujita T; Tsuji T
    Clin Exp Immunol; 1996 May; 104(2):286-92. PubMed ID: 8625522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b.
    Tse PK; Lee YL; Chow WN; Luk JM; Lee KF; Yeung WS
    Endocrinology; 2008 Mar; 149(3):1268-76. PubMed ID: 18039777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.